Trial record 1 of 1 for:    NCT00895583
Previous Study | Return to List | Next Study

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00895583
First received: April 29, 2009
Last updated: September 16, 2013
Last verified: September 2013
  Purpose

This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.


Condition Intervention Phase
Graft Rejection
Kidney Transplant
Renal Allograft Recipients
Renal Transplant
Drug: Tacrolimus
Drug: Sirolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percent of subjects who demonstrate a greater than or equal to 5 ml/min/1.73m2 improvement in calculated glomerular filtration rate (GFR). [ Time Frame: From randomization to 24 months post-transplant ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Composite rate of the first occurrence of biopsy-confirmed acute rejection (BCAR), graft loss, or death. [ Time Frame: From randomization to 24 months post-transplant ] [ Designated as safety issue: Yes ]

Enrollment: 253
Study Start Date: June 2009
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group I - Planned transition to sirolimus from tacrolimus Drug: Tacrolimus
During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
Other Name: Prograf, Adagraf
Drug: Sirolimus
Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
Other Name: Rapamune
Active Comparator: Group II - Continuation of tacrolimus Drug: Tacrolimus
During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
Other Name: Prograf, adagraf

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

At Screening:

  • Male or female subjects aged 18 years or older.
  • Recipients who are 14 days prior to transplantation up through 14 days after transplantation.
  • Recipients of a primary, living- or deceased-donor renal allograft.
  • All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 3 months after the last dose of test article. A subject is biologically capable of having children even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.

At Randomization:

  • Ninety (90) to 150 days post-transplantation.
  • Treatment with tacrolimus and an inosine monophosphate dehydrogenase (IMPDH) inhibitor initiated less than or equal to 30 days of transplantation and has remained on both for the 30 days prior to randomization.

Exclusion Criteria:

At Screening:

  • Recipients of multiple organ transplants (i.e., any prior or concurrent transplantation of any organs including prior renal transplant. )
  • Recipients of adult or pediatric en bloc kidney transplants.
  • Recipients who required or will require desensitization protocols.
  • Known history of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis (MPGN).
  • Evidence of active systemic or localized major infection, as determined by the investigator.
  • Received any investigational drugs or devices less than or equal to 30 days prior to transplantation.
  • Known or suspected allergy to sirolimus (SRL), tacrolimus (TAC), inosine-monophosphate dehydrogenase (IMPDH) inhibitor, macrolide antibiotics, iothalamate, iodine, iodine-containing products, including contrast media other compounds related to these products/classes of medication, or shellfish.
  • History of malignancy less than or equal to 3 years of screening (except for adequately treated basal cell or squamous cell carcinoma of the skin).
  • Recipients who are known to be human immunodeficiency virus (HIV) positive.
  • Women who are biologically capable of having children with a positive urine or serum pregnancy test at screening.
  • Breastfeeding women.

At Randomization:

  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.
  • Planned treatment with immunosuppressive therapies other than those described in the protocol.
  • Subjects who underwent corticosteroids withdrawal or avoidance and did not receive antibody induction at the time of transplantation with anti-thymocyte globulin (rabbit) (rATG) (Thymoglobulin®), anti-thymocyte globulin (equine) (Atgam®), or alemtuzumab (Campath®).
  • Subjects who have had corticosteroid (CS) discontinued less than or equal to 30 days before randomization.
  • Calculated glomerular filtration rate (GFR) less than 40 mL/min/1.73m2 using the simplified Modification of Diet in Renal Disease (MDRD) formula less than or equal to 2 weeks prior to randomization.
  • Spot urine protein to creatinine ratio (UPr/Cr) greater than or equal to 0.5 less than or equal to 2 weeks prior to randomization.
  • Banff (2007) grade 2 or higher acute T-cell-mediated or any acute antibody-mediated rejection at any time post-transplantation.
  • Any acute rejection (biopsy-confirmed or presumed) less than or equal to 30 days before randomization.
  • More than 1 episode of acute rejection (biopsy-confirmed or presumed).
  • Known Banff (2007) interstitial fibrosis and tubular atrophy (IF/TA) greater than or equal to grade 2 or recurrent/de novo glomerular disease.
  • Major surgery less than or equal to 2 weeks prior to randomization.
  • Active post-operative complication, e.g. infection, delayed wound healing.
  • Total white blood cell count less than 2,000/mm3 or absolute neutrophil count (ANC) less than 1000 or platelet count less than 100,000/mm3 less than or equal to 2 weeks prior to randomization.
  • Fasting triglycerides greater than 400 mg/dL (greater than 4.5 mmol/L) or fasting total cholesterol greater than 300 mg/dL (greater than 7.8 mmol/L) less than or equal to 2 weeks prior to randomization regardless of whether or not on lipid-lowering therapy.
  • Women who are biologically capable of having children with a positive urine or serum pregnancy test at randomization.
  • Breastfeeding women.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00895583

  Hide Study Locations
Locations
United States, California
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
San Francisco, California, United States, 94115
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
Pfizer Investigational Site
Denver, Colorado, United States, 80230
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60611
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States, 40536
United States, Maine
Pfizer Investigational Site
Portland, Maine, United States, 04102
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site
Detroit, Michigan, United States, 48236
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10032
Pfizer Investigational Site
Rochester, New York, United States, 14642
United States, North Carolina
Pfizer Investigational Site
Chapel Hill, North Carolina, United States, 27599 7155
Pfizer Investigational Site
Durham, North Carolina, United States, 27705
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45267-0589
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45267-0595
Pfizer Investigational Site
Cleveland, Ohio, United States, 44106
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
United States, Texas
Pfizer Investigational Site
Houston, Texas, United States, 77030
United States, Virginia
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22908
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22901
Pfizer Investigational Site
Richmond, Virginia, United States, 23298
Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, Buenos Aires, Argentina, C1425APQ
Australia, New South Wales
Pfizer Investigational Site
Randwick, New South Wales, Australia, 2031
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Western Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia, 6009
Brazil
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90035-074
Pfizer Investigational Site
Bela Vista, Sao Paulo, Brazil, 01323-030
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 04038-002
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 01323-000
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 04039-033
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 01323-001
Germany
Pfizer Investigational Site
Berlin, Germany, 10117
Italy
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Milano, Italy, 20162
Spain
Pfizer Investigational Site
Barcelona, Spain, 08907
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Santander, Spain, 39008
Pfizer Investigational Site
Valencia, Spain, 46026
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00895583     History of Changes
Other Study ID Numbers: 0468E8-4500, B1741007
Study First Received: April 29, 2009
Last Updated: September 16, 2013
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Depart

Keywords provided by Pfizer:
renal transplant
immunosuppression
sirolimus/rapamune
planned transition

Additional relevant MeSH terms:
Sirolimus
Everolimus
Tacrolimus
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on April 17, 2014